Clinical trials: Hormone-Sensitive Prostate Cancer
Prostate Cancer
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer
PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.
- Trial name
- PET-MaN (NCT05161728)
- Testing
- PSMA-PET/CT
- Where
- 4 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Roderick van den Bergh
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT06312670
- Testing
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pedro Barata, MD, MSc
Prostate Cancer
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on…
- Trial name
- NCT05705700
- Testing
- Dutasteride, Abiraterone
- Sponsor
- Masonic Cancer Center, University of Minnesota
Oligometastatic Hormone-Sensitive Prostate Cancer, Prostate Adenocarcinoma
Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy
MAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate…
- Trial name
- MAZINGA (NCT07766486)
- Testing
- Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
- Trial name
- PRIME (NCT07146113)
- Where
- 16 sites in Russia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
MRD, Prostate Cancer
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
- Conditions
- MRD, Prostate Cancer, mHSPC
- Trial name
- NCT07112612
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
The purpose of this study is to learn about how long apalutamide and enzalutamide are taken by men to treat mCSPC. Prostate cancer is one of the most common cancers in men.
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms, Prostate Cancer
- Trial name
- NCT07086651
- Testing
- Enzalutamide, Apalutamide
- Where
- United States
- Volunteers
- 1,300 people
- Sponsor
- Pfizer
Hormone Sensitive Prostate Cancer, Prostate Cancer
Cardiovascular Events in GnRH Agonist vs. Antagonist
The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared to Gonadotropin-releasing hormone (GnRH) agonists in patients with advanced prostate cancer…
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cardiac Event
- Trial name
- NCT04182594
- Testing
- Degarelix, GnRH agonist
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Rabin Medical Center
Prostate Cancer, Prostate Cancer Recurrent
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- DART (NCT04641078)
- Testing
- Darolutamide, metastasis-directed treatment
- Where
- 8 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Ghent
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
This is a prospective, interventional, non-randomized, phase 2 study to assess oncologic outcomes of metastatic hormone-sensitive prostate cancer (mCSPC) patients who receive a risk-adapted treatment approach followed by…
- Trial name
- RISK-ADAPT (NCT07645326)
- Testing
- Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Georgetown University
Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are…
- Trial name
- NCT04619069
- Testing
- SBRT, Hormone therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Castration-sensitive Prostate Cancer
Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan
To evaluate changes in genomic alterations for 73 PC driver genes during apalutamide treatment
- Trial name
- CUARTET (NCT04601441)
- Testing
- Apalutamide
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kindai University
Prostate Cancer
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
- Trial name
- TITAN (NCT02489318)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 220 sites in United States, Argentina and 20 more
- Volunteers
- 1,052 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer, Metastatic Cancer
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Prostate cancer remains the most common malignancy in men in Europe. Over the last two decades, the treatment landscape for both localized and metastatic prostate cancer has been revolutionized.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer
- Trial name
- PSA-DEEP02 (NCT06652607)
- Testing
- Enzalutamide, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of [18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in…
- Trial name
- NCT05245435
- Testing
- FDHT-PET Scan, liquid biopsies
- Where
- Austria
- Sponsor
- Medical University of Vienna
Metastatic Hormone-sensitive Prostate Cancer
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by…
- Trial name
- ARASEC (NCT05059236)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 31 sites in United States
- Volunteers
- 223 people
- Sponsor
- Bayer
Metastatic Prostate Cancer
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate…
- Trial name
- ZZ-First (NCT04332744)
- Testing
- Enzalutamide, Talazoparib
- Where
- 8 sites in Spain
- Volunteers
- 54 people
- Sponsor
- MedSIR
Prostate Cancer Metastatic
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
Despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human de novo PCa pathogenesis.
- Trial name
- NCT05530395
- Testing
- Testosterone levels
- Where
- 3 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Ignacio Puche Sanz
Metastatic Hormone-Sensitive Prostate Cancer
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order…
- Trial name
- RASTOM (NCT06134271)
- Testing
- Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment
- Volunteers
- 160 people
- Sponsor
- Jianbin Bi
Prostate Cancer Metastatic Disease, PET / CT
The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024.
- Trial name
- NCT06915714
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University